-+ 0.00%
-+ 0.00%
-+ 0.00%

Apogee Q1 FY26 net loss widens to $74.1 million

PUBT·05/11/2026 11:03:28
Listen to the news
Apogee Q1 FY26 net loss widens to $74.1 million
  • Apogee Therapeutics posted a net loss of USD 74.1 million for first-quarter 2026, widening from USD 55.3 million a year earlier.
  • Operating loss widened to USD 82.8 million from USD 63.1 million, as R&D expenses climbed to USD 60.8 million from USD 46.4 million.
  • G&A costs increased to USD 22 million from USD 16.7 million, while interest income rose to USD 8.7 million from USD 7.8 million.
  • Cash, cash equivalents and marketable securities totaled USD 1.3 billion at March 31, up from USD 902.9 million at Dec. 31, after an upsized USD 403 million public equity offering; runway forecast into 2029.
  • APEX Phase 2 Part B 16-week data for zumilokibart in atopic dermatitis expected in Q2 2026, with Phase 3 initiation planned for the second half of 2026 and additional asthma and eosinophilic esophagitis trial details due later this year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110700PRIMZONEFULLFEED9715695) on May 11, 2026, and is solely responsible for the information contained therein.